Cancer clinical trials in the region Grand Est

286 currently recruiting clinical trials
Region Grand Est
Phase 3 Multiple myeloma #NCT05519085 #2023-509859-13-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
Celgene
Phase 3 Multiple myeloma #NCT06918002 #2024-516418-39-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
56 recruiting sites
Intergroupe Francophone du Myélome
Phase 3 Multiple myeloma #NCT05552222 #2022-000909-28
Required histologic types
Symptomatic multiple myeloma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
9 recruiting sites
Janssen
Phase 3 Amyloidosis #NCT07052903 #2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3 Thyroid and adrenal gland cancer #NCT04290663 #2024-514603-34-00
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Radioactive iodine
28 recruiting sites
Centre François Baclesse
Phase 3 Thyroid and adrenal gland cancer #NCT03583710
Required histologic types
Adrenal gland cancer
Required histologic sub types
Adrenocortical carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Chemotherapy Radiotherapy Mitotane
10 recruiting sites
M.D. Anderson Cancer Center
Phase 3 Lung cancer #NCT04613596 #2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06465953 #2023-510155-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required IPSS-M prognostic scores
Low Moderately low Moderately high High Very high
Excluded previous treatments
Chemotherapy Allogeneic stem cell transplant
6 recruiting sites
Servier
Phase 3 Head and neck cancer #NCT06496178 #2023-510322-32-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
16 recruiting sites
Merus
Phase 3 Kidney cancer #NCT07011719 #2024-515023-11-00
Required histologic types
Clear cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
9 recruiting sites
Arcus Biosciences